Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460576 · ClinicalTrials.gov registry record
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 253
- Enrollment target
NCT01460576: Completed study, sponsored by Vanderbilt University Medical Center.
NCT01460576 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 253 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01460576 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 253 participants
- Enrollment target
Study Summary
The goal of IMPROV is to identify molecular mechanisms that contribute to lung injury and long-term breathing problems in preterm infants by investigating two interrelated biochemical pathways: the urea cycle-nitric oxide pathway and the glutathione pathway. The investigators hypothesize that prematurity-related limitations in the function of these important biochemical pathways contribute to respiratory disease risk over the first year of life.
Primary Outcome
Need for oxygen, respiratory medications, hospital admissions for respiratory disease or a positive response in at least 1 of 4 morbidity domains during at least 2 separate parental interviews.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 253 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-12 |
What the finished NCT01460576 record still lists
NCT01460576 is an observational study that tracks outcomes without assigning an intervention. The registered 253 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01460576 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01460576 about?
NCT01460576 is a clinical study titled "Improving Prematurity-Related Respiratory Outcomes at Vanderbilt". The goal of IMPROV is to identify molecular mechanisms that contribute to lung injury and long-term breathing problems in preterm infants by investigating two interrelated biochemical pathways: the urea cycle-nitric oxide pathway and the glutathione pathway. The investigators hypothesize that premat...
What is the current status of trial NCT01460576?
This trial is currently completed. The enrollment target is 253 participants. The study started on 2011-09. Estimated completion is 2016-12.
Who is sponsoring clinical trial NCT01460576?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia